Navigation Links
Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
Date:3/4/2011

SAN DIEGO, March 4, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report fourth quarter and 2010 financial results on Friday March 11, 2011 before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PT (11:00 a.m. ET), which will be simultaneously broadcast over the Internet. Management will discuss the financial results and highlights for the fourth quarter of 2010 and provide a product pipeline update.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

To participate by telephone, please dial 877.407.8037 for domestic callers or 201.689.8037 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company's Web site at www.halozyme.com. Shortly after the call an audio replay will be available on Halozyme's Web site for seven days. A telephone replay will be available by dialing 877.660.6853 from the U.S., or 201.612.7415 for international callers and using account # 367 and ID # 368697.  

About Halozyme Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze technology to Roche's biological therapeutics, including Herceptin® and MabThera®, and with Baxter BioScience to apply Enhanze technology to immunoglobulin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com. Halozyme ContactRobert H. UhlSenior Director, Investor Relations(858) 704-8264ruhl@halozyme.com
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
2. Halozyme Therapeutics Realigns Management
3. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
4. Halozyme Therapeutics Announces Implementation of Development Focused Strategy
5. Halozyme Therapeutics to Host Analyst Meeting on October 14 in New York
6. Halozyme Therapeutics Announces Public Offering of Common Stock
7. Halozyme Provides HYLENEX® Product Reintroduction Update
8. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
9. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
10. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
11. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
(Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/27/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, ... and efficacy studies. The company is harnessing the power ... MAGE A, in an effort to find a better ... After 4 weeks of treatment in transgenic mice, the ... in a full toxicology report of various organs. Cytotoxic ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 29, 2017 , ... The ... Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, ... questions regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... services, is proud to announce it has joined the National Association for Home ... interests of chronically ill, disabled, and dying Americans of all ages and the ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Alert Sentry ... of MPERS (Mobile Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These ... market. The first of their kind, the iSAFE and iSAFE Plus offer direct GPS ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of ... However, for those self-conscious about a double chin, this means more anxiety than elation. ... , “For most people, a double chin is undesirable,” Dr. Goldman said, “but ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
Breaking Medicine News(10 mins):